1st Counsel – Lifestyle

Author: Prime Movers Lab

Gilgamesh Pharma Closes Oversubscribed $60 Million Series A to Develop Next Generation Neuropsychiatric Therapies

March 24, 2026

All content ©2025 Tork Media
All Rights Reserved. For more information on this site, please read our Privacy Policy, Terms of Service, Cookie Policy, and Ad Choices.